Danielle Valletti, Assistant Editor

The FDA removed the age requirement from the neffy 1-mg label, allowing use based solely on weight and expanding access to younger pediatric patients at risk for anaphylaxis.

ABBV-744 BD2-selective BET inhibitor shows early spleen and symptom gains with manageable cytopenias in a phase 1b trial.

Albuminuria (uACR) flags early vascular damage linking chronic kidney disease and cardiovascular risk.

Ahead of the Sports Pharmacy Summit, a pharmacist weighs GLP-1s for athlete weight management benefits.

Learn why uACR screening flags early vascular damage linking chronic kidney disease and cardiovascular health.

Evidence questions anemia plus thrombocytopenia prognosis in primary myelofibrosis, helping oncology pharmacists refine hematology risk stratification.

Tucatinib triplet regimen with trastuzumab and capecitabine boosts survival and cerebrospinal fluid control in HER2-positive breast cancer leptomeningeal metastasis.

FDA approval of linerixibat brings the first targeted oral relief for cholestatic pruritus in primary biliary cholangitis, easing relentless autoimmune itch fast.

Olympic athlete Tabitha Peterson, PharmD, reveals how sports pharmacy helps athletes avoid antidoping risks, manage supplements safely, and stay competition-ready.

Real-world data show racial gaps in multiple myeloma CAR T-cell therapy; pharmacists in oncology can boost referrals, equity, and access.

PharmD and Olympian Tabitha Peterson reveals how pharmacy analytics, teamwork, and constant learning fuel elite curling strategy and Olympic-level performance.

Tabitha Peterson, PharmD, discusses how teamwork, strategy, and antidoping expertise sharpen patient care and athlete safety.

Ruxolitinib can shape myelofibrosis care, and other drugs' dosing, resistance, and next-generation combinations are under study.

Data from a phase 2 response-adapted trial identify CD38 expression, plasma cell phenotype, and immune microenvironment as critical determinants of single-agent daratumumab efficacy.

Andrew Shao, PhD, senior vice president for global regulatory and scientific affairs at Niagen Bioscience, discusses how increased consumer access to information has shifted the supplement landscape toward greater demand for clinically validated products and transparency. He highlights the critical role pharmacists play in guiding consumers toward evidence-based supplements, while emphasizing the need for stronger regulatory enforcement and industry accountability to improve trust and product quality.

Ipsen discontinues tazemetostat after SYMPHONY-1 safety signals; pharmacists and FDA guide next steps for EZH2-mutant follicular lymphoma patients.

Niagen Bioscience’s NAD research, patents, and clinical trials, plus pharmacist-led supplement education to help consumers choose evidence-based vitamins and supplements.

The FDA approves Bristol Myers Squibb’s deucravacitinib (Sotyktu), a first oral tyrosine kinase 2 inhibitor for active psoriatic arthritis.

Explore how limited FDA enforcement impacts vitamins and supplements, as pharmacists push industry transparency with independent testing, COAs, and research-backed quality.

Circulating tumor cells detected in peripheral blood may serve as a powerful prognostic biomarker in newly diagnosed multiple myeloma.

Pembrolizumab neoadjuvant immunotherapy hits approximately 70% complete responses in desmoplastic melanoma.

A Baptist Health pharmacy expert shares real-world myelofibrosis oncology tips on JAK selection, symptom control, and navigating specialty drug costs.

Consumers seek clinically validated supplements as health information spreads quickly; Niagen Bioscience stresses independent evidence, and pharmacists guide choices using trusted certifications.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, FASTCT, discusses the importance of advocacy for oncology pharmacists in both patient care and professional recognition. She highlights practical ways pharmacists can advocate—such as refining an elevator pitch, participating in virtual Hill Days, and partnering with professional organizations such as ASHP and HOPA.

Long-term care pharmacies optimize medication, vaccines, and safer therapies to boost patient care, cut risks, and navigate Medicare barriers.

Neoadjuvant pembrolizumab reshapes desmoplastic melanoma care, spotlighting sequence integrity, pharmacist-led toxicity readiness, and oncology networks accelerating rare-cancer immunotherapy innovation.

Oral bacteria such as Fusobacterium nucleatum may fuel breast cancer. Here's what pharmacists should know about periodontal health and genetic risk.

Artificial intelligence helps hematology teams and pharmacists distinguish prefibrotic myelofibrosis from essential thrombocythemia, improving the accuracy of myeloproliferative neoplasm diagnosis and oncology care.

Explore PREVENT Risk Equations reshaping hypertension care, HFpEF therapy, and CKD-related hyperkalemia.